Literature DB >> 24604758

Early results of robotic assisted nasopharyngectomy for recurrent nasopharyngeal carcinoma.

Raymond K Tsang1, Victor S To1, Ambrose C Ho1, Wai-Kuen Ho1, Jimmy Y Chan1, William I Wei1.   

Abstract

BACKGROUND: Minimally invasive nasopharyngectomy with the da Vinci surgical robot has been shown to be a feasible operation for salvage of recurrent nasopharyngeal carcinoma. The current case series presents the early results of robotic nasopharyngectomy.
METHODS: We conducted a prospective series of patients who underwent robotic nasopharyngectomy for recurrent nasopharyngeal carcinoma in a single institution.
RESULTS: Twelve patients underwent robotic nasopharyngectomy. The median operating time was 225 minutes. Median follow-up time was 23.8 months. Nine patients had clear resection margins, 2 patients had close margins, and 1 patient had positive margin. Two patients developed local recurrence and 1 patient had distant metastasis. Two patients in the cohort died of unrelated causes. The 2-year local control rate was 86%. The 2-year overall survival and disease-free survival was 83% and 61%, respectively.
CONCLUSION: Early results of robotic nasopharyngectomy showed a high local control rate. The operating time was comparable to open surgery and morbidities were low.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  nasopharyngeal carcinoma; nasopharyngectomy; transoral robotic surgery

Mesh:

Year:  2014        PMID: 24604758     DOI: 10.1002/hed.23672

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  12 in total

1.  Is the Da Vinci Xi system a real improvement for oncologic transoral robotic surgery? A systematic review of the literature.

Authors:  Giacomo Fiacchini; Matteo Vianini; Iacopo Dallan; Luca Bruschini
Journal:  J Robot Surg       Date:  2020-08-04

Review 2.  [Robot-assisted head and neck surgery].

Authors:  P J Schuler; F Boehm; L R Schild; J Greve; T K Hoffmann
Journal:  HNO       Date:  2021-02       Impact factor: 1.284

3.  Outcomes of Recurrent Nasopharyngeal Carcinoma Patients Treated With Salvage Surgery: A Meta-Analysis.

Authors:  Yekai Feng; Zhimei Dai; Ruicheng Yan; Feng Li; Xiaosheng Zhong; Haoxin Ye; Caiqing Chen; Shaochong Fan; Cheng Qing; Yong Pan; Haiying Sun
Journal:  Front Oncol       Date:  2021-10-08       Impact factor: 6.244

4.  Transoral robotic-assisted surgery for the approach to anterior cervical spine lesions.

Authors:  Gabriele Molteni; Marco Giuseppe Greco; Livio Presutti
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-09-01       Impact factor: 2.503

5.  Long-term outcomes and safety after reirradiation in locally recurrent nasopharyngeal carcinoma in a non-endemic area.

Authors:  J Boustani; A Ruffier; A Moya-Plana; Y Tao; F Nguyen; C Even; C Berthold; O Casiraghi; S Temam; P Blanchard
Journal:  Strahlenther Onkol       Date:  2020-06-08       Impact factor: 3.621

Review 6.  Salvage surgery for nasopharyngeal cancer.

Authors:  Raymond K Tsang; William I Wei
Journal:  World J Otorhinolaryngol Head Neck Surg       Date:  2015-10-24

Review 7.  Recommendations for surgical management of recurrent nasopharyngeal carcinoma during COVID-19 pandemic.

Authors:  Velda Ling Yu Chow; Jimmy Yu Wai Chan; Stanley Thian Sze Wong; William Ignace Wei
Journal:  Laryngoscope Investig Otolaryngol       Date:  2020-06-13

Review 8.  Novel Therapies Boosting T Cell Immunity in Epstein Barr Virus-Associated Nasopharyngeal Carcinoma.

Authors:  Sarah Renaud; Anthony Lefebvre; Serge Mordon; Olivier Moralès; Nadira Delhem
Journal:  Int J Mol Sci       Date:  2020-06-16       Impact factor: 5.923

Review 9.  Recent advances in the management of nasopharyngeal carcinoma.

Authors:  W K Jacky Lam; Jason Y K Chan
Journal:  F1000Res       Date:  2018-11-21

Review 10.  Recurrent Nasopharyngeal Cancer: Critical Review of Local Treatment Options Including Recommendations during the COVID-19 Pandemic.

Authors:  Michaela Svajdova; Marian Sicak; Pavol Dubinsky; Marek Slavik; Pavel Slampa; Tomas Kazda
Journal:  Cancers (Basel)       Date:  2020-11-25       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.